The Polycythemia Vera market is expected to experience continued growth as increasing disease awareness, evolving treatment approaches, and the development of novel therapies create new opportunities. Emerging treatments such as rusfertide, givinostat, bomedemstat, SLN124, sapablursen, and PPMX-T003 are expected to influence the future treatment landscape.

DelveInsight's recently published “Polycythemia Vera Market Insights, Epidemiology, and Market Forecast-2034” report provides a comprehensive assessment of the Polycythemia Vera market, including current treatment practices, emerging therapies, epidemiology, market trends, and forecasted market size across the seven major markets (7MM): the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Polycythemia Vera Market Summary

  • According to DelveInsight's analysis, the Polycythemia Vera market size was approximately USD 1.9 billion in the 7MM in 2024 and is anticipated to grow during the forecast period (2020–2034).
  • The United States accounted for the highest number of Polycythemia Vera cases among the 7MM in 2023, with approximately 180,000 prevalent cases.
  • In the EU4 and the United Kingdom, Germany had the highest number of Polycythemia Vera cases, with nearly 25,000 cases in 2023, while Spain reported the lowest number of cases.
  • According to Orphanet, Polycythemia Vera affects approximately 30 individuals per 100,000 people in Germany, translating to nearly 24,000 affected individuals when extrapolated to the country's population.
  • Several emerging therapies are expected to influence the Polycythemia Vera treatment landscape, including rusfertide (PTG-300), givinostat, bomedemstat, SLN124, sapablursen, and PPMX-T003.
  • Key companies involved in Polycythemia Vera drug development include Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharmaceutical, Perseus Proteomics, Novartis, PharmaEssentia, AOP Orphan Pharmaceuticals, Incyte Corporation, and others.
  • The Polycythemia Vera market is expected to benefit from the development of novel therapies targeting disease biology and treatment-related challenges.

Get a Free Sample for the Polycythemia Vera Market Report @
Polycythemia Vera Market Report

Key Factors Driving the Growth of the Polycythemia Vera Market

Rising Disease Burden

Polycythemia Vera continues to represent an important hematological disorder within the myeloproliferative neoplasm landscape. The United States had the highest number of cases among the 7MM in 2023, while Germany represented the leading country within the EU4 and the United Kingdom.

The continued identification and diagnosis of patients, together with growing disease awareness, are expected to support demand for effective long-term treatment options.

Increasing Focus on Novel Treatment Approaches

The Polycythemia Vera treatment landscape is gradually moving toward therapies that can address important disease-management challenges. Existing treatments may not be suitable or sufficiently effective for every patient, creating opportunities for novel mechanisms of action.

According to Kuykendall (2023), up to 25% of patients may develop resistance to or intolerance of hydroxyurea, highlighting an important unmet need and supporting continued research into alternative treatment strategies.

Development of Emerging Therapies

The Polycythemia Vera market is expected to become increasingly competitive as pipeline therapies progress through clinical development. Candidates such as rusfertide, givinostat, bomedemstat, SLN124, sapablursen, and PPMX-T003 are being evaluated for their potential to address important treatment gaps.

Polycythemia Vera Market Analysis

The Polycythemia Vera market is undergoing a period of therapeutic development, supported by advances in understanding disease biology and increasing investment in targeted treatment approaches.

Rusfertide, developed by Protagonist Therapeutics, represents one of the most closely watched emerging therapies in the Polycythemia Vera pipeline. The investigational therapy is a hepcidin mimetic designed to help manage erythrocytosis and reduce the need for frequent phlebotomy.

In January 2026, a New Drug Application (NDA) was filed with the U.S. FDA for rusfertide for the treatment of adults with Polycythemia Vera. The submission was supported by findings from the Phase III VERIFY trial and the Phase II REVIVE trial. The VERIFY study evaluated rusfertide in combination with standard of care and reported positive results across its primary and key secondary endpoints.

The competitive landscape is also being influenced by other emerging therapies. Givinostat, developed by Italfarmaco, received FDA Fast Track designation in May 2025 for Polycythemia Vera. Meanwhile, VGT-1849B, a JAK2 inhibitor developed by Vanda Pharmaceuticals, received FDA Orphan Drug Designation in August 2025 for the treatment of Polycythemia Vera.

These developments highlight the growing focus on therapies with differentiated mechanisms and the potential to improve disease control.

Polycythemia Vera Competitive Landscape

Some of the key companies developing or evaluating therapies for Polycythemia Vera include Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharmaceutical, Perseus Proteomics, Novartis, PharmaEssentia, AOP Orphan Pharmaceuticals AG, Incyte Corporation, and others.

Rusfertide (PTG-300): Protagonist Therapeutics

Rusfertide is an investigational hepcidin mimetic peptide designed to address erythrocytosis in patients with Polycythemia Vera. Its development is focused on improving hematocrit control and reducing the burden associated with phlebotomy.

In August 2025, the FDA granted Breakthrough Therapy Designation to rusfertide for the treatment of erythrocytosis in Polycythemia Vera patients with limited therapeutic options.

Givinostat (ITF2357): Italfarmaco

Givinostat is an investigational therapy being evaluated for Polycythemia Vera. In May 2025, the FDA granted Fast Track designation to givinostat for the indication, supporting its continued development in the Polycythemia Vera treatment landscape.

Bomedemstat: Imago BioSciences

Bomedemstat is another emerging therapy being evaluated for Polycythemia Vera. Its development reflects the increasing focus on novel approaches that may address the underlying biology of myeloproliferative neoplasms.

SLN124: Silence Therapeutics

Silence Therapeutics is developing SLN124, an siRNA-based therapeutic approach targeting pathways relevant to Polycythemia Vera. Additional clinical findings from the SANRECO study have contributed to the evolving understanding of RNA-based approaches in the disease.

Sapablursen: Ionis Pharmaceutical

Ionis Pharmaceutical is developing sapablursen, another investigational candidate being evaluated as part of the broader pipeline of emerging Polycythemia Vera therapies.

PPMX-T003: Perseus Proteomics

PPMX-T003 is an emerging therapeutic candidate being evaluated for Polycythemia Vera, further contributing to the competitive pipeline and diversification of potential treatment mechanisms.

Discover more about the emerging Polycythemia Vera therapies @
Polycythemia Vera Treatment Market

Recent Developments in the Polycythemia Vera Market

  • January 2026: A New Drug Application was filed with the FDA for rusfertide for the treatment of adults with Polycythemia Vera. The submission was supported by results from the Phase III VERIFY and Phase II REVIVE studies.
  • November 2025: SOTIO Biotech announced preclinical findings for SOT106 at the Connective Tissue Oncology Society Annual Meeting.
  • August 2025: The FDA granted Breakthrough Therapy Designation to rusfertide for the treatment of erythrocytosis in Polycythemia Vera.
  • August 2025: Vanda Pharmaceuticals announced that VGT-1849B received FDA Orphan Drug Designation for Polycythemia Vera.
  • May 2025: The FDA granted Fast Track designation to givinostat for the treatment of Polycythemia Vera.
  • March 2025: Protagonist Therapeutics and Takeda announced positive topline results from the Phase III VERIFY study of rusfertide.
  • December 2024: Silence Therapeutics announced additional results from the Phase I open-label segment of the SANRECO study evaluating divesiran in patients with Polycythemia Vera.
  • June 2024: AOP Health presented updated findings from the PROUD-PV and CONTINUATION-PV trials evaluating ropeginterferon alfa-2b.
  • February 2024: Disc Medicine announced that the FDA granted Orphan Drug Designation to DISC-3405 for the treatment of Polycythemia Vera.
  • January 2024: Takeda and Protagonist Therapeutics established a global licensing and collaboration agreement for rusfertide.

What is Polycythemia Vera?

Polycythemia Vera (PV) is a rare, chronic blood disorder characterized by the abnormal overproduction of blood cells, particularly red blood cells, in the bone marrow. The resulting increase in blood cell concentration can make the blood thicker and increase the risk of complications such as blood clots.

Polycythemia Vera belongs to a group of blood cancers known as myeloproliferative neoplasms, in which the bone marrow produces excessive numbers of blood cells. Long-term disease management focuses on controlling blood counts and reducing the risk of complications.

To know more about the Polycythemia Vera market outlook, drug uptake, treatment scenario, and epidemiology trends @ Polycythemia Vera Market Forecast

Polycythemia Vera Epidemiology

The Polycythemia Vera epidemiology section provides historical, current, and forecasted epidemiological insights across the 7MM during the study period 2020–2034.

In 2023, the United States had approximately 180,000 prevalent Polycythemia Vera cases, representing the largest patient population among the seven major markets.

Within the EU4 and the United Kingdom, Germany had the highest number of cases, with nearly 25,000 cases in 2023.

The Polycythemia Vera epidemiology analysis is segmented into:

  • Total Prevalence of Polycythemia Vera
  • Prevalent Cases of Polycythemia Vera by Severity
  • Gender-specific Prevalence of Polycythemia Vera
  • Diagnosed Cases of Episodic and Chronic Polycythemia Vera

Download the report to understand Polycythemia Vera epidemiology trends @ Polycythemia Vera Epidemiology Forecast

Polycythemia Vera Drugs Uptake and Pipeline Development Activities

The drug uptake section of the report evaluates the expected adoption of recently launched and emerging therapies during the forecast period. The analysis includes drug-specific market uptake, patient uptake, sales, and market share.

The report also provides an assessment of the Polycythemia Vera pipeline, covering therapies across different stages of clinical development and the companies responsible for their development.

In addition, the pipeline analysis examines important industry developments, including collaborations, licensing agreements, acquisitions, mergers, patent information, and other strategic activities that may influence the market.

Polycythemia Vera Therapies and Key Companies

  • Rusfertide (PTG-300): Protagonist Therapeutics
  • Givinostat (ITF2357): Italfarmaco
  • Bomedemstat: Imago BioSciences
  • SLN124: Silence Therapeutics
  • Sapablursen: Ionis Pharmaceutical
  • PPMX-T003: Perseus Proteomics
  • PTG-300: Protagonist Therapeutics, Inc.
  • SLN124: Silence Therapeutics plc
  • Hydroxyurea: Novartis
  • Ropeginterferon alfa-2b: PharmaEssentia
  • PEG-P-INF alpha-2b (P1101): AOP Orphan Pharmaceuticals AG
  • Ruxolitinib: Incyte Corporation

Discover more about therapies expected to capture Polycythemia Vera market share @ Polycythemia Vera Treatment Market

Polycythemia Vera Market Strengths

  • The approval of BESREMi in the United States and its potential expansion across additional treatment settings provide an opportunity for interferon-based therapy to strengthen its position in the Polycythemia Vera market.
  • Increasing adoption of JAKAFI/JAKAVI supports its potential to remain an important therapy for patients requiring second-line treatment.

Polycythemia Vera Market Opportunities

  • Increasing strategic alliances, including geographical partnerships and licensing agreements, may support the development and commercialization of emerging therapies.
  • FDA designations such as Breakthrough Therapy Designation and Fast Track designation can support accelerated development pathways for promising candidates.
  • Novel therapies with differentiated or disease-modifying mechanisms and improved tolerability may address important unmet needs in Polycythemia Vera.

Scope of the Polycythemia Vera Market Report

  • Study Period: 2020–2034
  • Coverage: 7MM 
  • Key Polycythemia Vera Companies: Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharmaceutical, Perseus Proteomics, Novartis, PharmaEssentia, AOP Orphan Pharmaceuticals AG, Incyte Corporation, and others
  • Key Polycythemia Vera Therapies: Rusfertide (PTG-300), Givinostat (ITF2357), Bomedemstat, SLN124, Sapablursen, PPMX-T003, Hydroxyurea, Ropeginterferon alfa-2b, PEG-P-INF alpha-2b (P1101), Ruxolitinib, and others
  • Polycythemia Vera Therapeutic Assessment: Current marketed and emerging therapies
  • Polycythemia Vera Market Dynamics: Market drivers and market barriers
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's Five Forces, BCG Matrix, and market entry strategies
  • Unmet Needs: KOL views, analyst views, market access, and reimbursement

To learn more about companies working in the Polycythemia Vera treatment market @ Polycythemia Vera Clinical Trials and Therapeutic Assessment

Table of Contents

  1. Polycythemia Vera Market Report Introduction
  2. Executive Summary for Polycythemia Vera
  3. SWOT Analysis of Polycythemia Vera
  4. Polycythemia Vera Patient Share (%) Overview at a Glance
  5. Polycythemia Vera Market Overview at a Glance
  6. Polycythemia Vera Disease Background and Overview
  7. Polycythemia Vera Epidemiology and Patient Population
  8. Country-Specific Patient Population of Polycythemia Vera
  9. Polycythemia Vera Current Treatment and Medical Practices
  10. Polycythemia Vera Unmet Needs
  11. Polycythemia Vera Emerging Therapies
  12. Polycythemia Vera Market Outlook
  13. Country-Wise Polycythemia Vera Market Analysis (2020–2034)
  14. Polycythemia Vera Market Access and Reimbursement of Therapies
  15. Polycythemia Vera Market Drivers
  16. Polycythemia Vera Market Barriers
  17. Polycythemia Vera Appendix
  18. Polycythemia Vera Report Methodology
  19. DelveInsight Capabilities
  20. Disclaimer
  21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on the life sciences industry. It supports pharma companies by providing comprehensive end-to-end solutions designed to improve business performance.

DelveInsight also offers Healthcare Consulting Services, supporting market analysis, strategic decision-making, and business growth while helping organizations address complex challenges with a practical and data-driven approach.

Contact Us

Kanishk

[email protected]